Alluvi, formerly LY3414901, represents a significant advancement in weight management. This combined-action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist https://alluvihealthcare310858.theroseblog.com/675470/alluvi-a-detailed-analysis-into-the-medication-s-potential